InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
22%
T+90 mean return
-19.5%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by McClung David Mark, EVP, directeur commercial et COO. Director active across 1 company, notably Sangamo Therapeutics, INC. Aggregated, 9 filings have been published. Activity tracked since 25 June 2021. The latest transaction was disclosed on 25 November 2023 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations9 total
1,925 shares@ US$0.38210.2% of flowCommon StockSEC:0001209191-23-056788:0
1,925 shares@ US$0.770.4% of flowCommon StockSEC:0001209191-23-047586:0
11,528 shares@ US$1.193.9% of flowCommon StockSEC:0001209191-23-039711:0
1,925 shares@ US$1.330.7% of flowCommon StockSEC:0001209191-23-032910:0
56,250 shares0Common StockSEC:0001209191-23-016395:0
11,525 shares@ US$4.310.032% mcap15.5% of flowCommon StockSEC:0001209191-22-039649:0
4,610 shares@ US$5.900.017% mcap8.0% of flowCommon StockSEC:0001209191-22-014167:0
11,525 shares@ US$12.0236.2% of flowCommon StockSEC:0001209191-21-043811
11,525 shares@ US$12.020.079% mcap38.2% of flowCommon StockSEC:0001209191-21-043811:0
9 of 9 declarations
About McClung David Mark
David Mark McClung is the EVP, Chief Business Officer, and COO at SANGAMO THERAPEUTICS, INC. He oversees the operations and business initiatives of the company.
